Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
On July 23, Genmab A/S (GMAB) and AbbVie Inc. (ABBV) released clarification regarding their joint clinical trial for epcoritamab (DuoBody-CD3xCD20). The Phase 3 EPCORE DLBCL-1 study aimed to evaluate epcoritamab monotherapy against chemoimmunotherapy in transplant-ineligible adults with relapsed/refractory diffuse large B-cell lymphoma.
The trial failed to meet its primary endpoint in the United States, where overall survival was the sole primary endpoint. Epcoritamab retains its accelerated FDA approval but the missing endpoint requires both companies to examine the full data set with regulators to determine the next steps. Genmab's first-half 2026 results revealed total revenue of $2.051 billion, a 25% year-over-year increase.
AbbVie reported $16.99 billion in net revenues for Q2 2026, a 10.2% year-over-year growth. Both companies have different financial profiles with AbbVie generating diversified cash flows and Genmab offering higher growth velocity but greater pipeline concentration risk.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
